Hi [[ session.user.profile.firstName ]]

Medical Research

  • Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers
    Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers Yaso Natkunam, MD, PhD, Professor of Pathology, Director of Hematopathology, Stanford University School of Medicine Recorded: Mar 29 2017 58 mins
    Join us for the March CDx Insights webinar “Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers.” Our speaker is Yaso Natkunam, MD, PhD, Professor of Pathology and Director of Hematopathology at Stanford University School of Medicine. Dr Natkunam will review key updates to the classifications of large B-cell lymphomas in the “2016 revision of the World Health Organization classification of lymphoid neoplasms.” She will also discuss the role of diagnostic and predictive biomarkers in DLBCL, high grade B-cell lymphoma and other large B-cell lymphomas.
  • Biosimilars - A Network perspective
    Biosimilars - A Network perspective Divya Chadha Manek Recorded: Mar 29 2017 15 mins
    A biosimilar medicine is a biological medicine which is highly similar to another biological medicine already licensed for use. It is a biological medicine which has been shown not to have any clinically meaningful differences from the originator biological medicine in terms of quality, safety and efficacy.
  • Unlocking the value of pharmacists to reach the right patients and consumers
    Unlocking the value of pharmacists to reach the right patients and consumers Pierre-Yves Boisvert, Paulien Schul, Nina Felton and Andrew McConaghie Recorded: Mar 29 2017 70 mins
    Pharmacists are highly trained healthcare professionals who have a deep understanding of medicines and daily contact with patients and consumers. This puts them in a unique position in terms of being able to maximise the benefits that patients get from their medicines – however, healthcare systems and pharmaceutical companies frequently overlook this potential.
    Pharmacists are especially well placed to help patients with multiple long-term conditions manage their health and medications, and pharmacist-led interventions have been shown to have a very significant impact on compliance and disease management in the community.
    We present a webinar debate in which our expert panel will discuss how pharmaceutical companies can work in collaboration with pharmacists in Europe to help patients make the most of their medicines, help generate data to prove the value of these interventions, and above all get the right medicine to the right patients and consumers.
    Join us and the PHOENIX group as we look at the practical steps needed to make this a reality. Key topics to be discussed include:
    •The challenges of identifying the right patient population across European markets
    •Understanding how pharmacists can play a greater role in patient care, e.g. improved adherence and outcomes
    •How optimum use of pharmacy level information can contribute to providing ‘real world’ evidence of treatments
  • NIHR Clinical Research Network support for Biosimilars clinical trials
    NIHR Clinical Research Network support for Biosimilars clinical trials Dr Sonya Abraham, Consultant Research Physician and Rheumatologist Recorded: Mar 29 2017 16 mins
    This presentation will discuss NIHR Clinical Research Network support for Biosimilar clinical trials. It begins with a background to biosimilars and the changing landscape in their drug development and regulatory pathways. It then focuses on the opportunities that the NHS via the NIHR CRNs can engage in biosimilar clinical trials across therapeutic indications.
  • Analytical Strategies for Comparability in Bioprocess Development
    Analytical Strategies for Comparability in Bioprocess Development Christine P. Chan, Ph.D & Joe Barco, Ph.D. Recorded: Mar 28 2017 71 mins
    Comparability exercises are commonly required at certain milestones during drug development as well as after product registration when changes are implemented into the manufacturing process. The goal is to evaluate if the product remains highly similar (not necessarily identical) before and after the change in terms of quality and stability and have no adverse impact on safety and efficacy predicted for the patients. This assessment requires product-specific knowledge gathered through drug development, taking a totality-of-evidence approach. The different levels of information are obtained from analytical studies for characterization of the molecule, animal studies for toxicity, pharmacokinetics and pharmacodynamics for pharmacological activities, and clinical studies for safety/tolerability, immunogenicity and efficacy. This Webinar discusses strategies and considerations for analytical characterization of protein structure and function which forms the foundation of the comparability demonstration.

    Sponsored by Unchained Labs

    Presentation Title: Limber up your lab with better tools for comparing biologics

    There’s no magic bullet when it comes to characterizing a protein by structure or function. Specific tests may work for one molecule but not the next. Instrumentation that provides a high degree of flexibility, balanced with low sample consumption and faster time to result, is crucial to keep up with ever changing laboratory needs. Unchained Labs puts biologics characterization front and center for our instrumentation development. We will discuss how our instruments let researchers be more flexible and efficient, while also providing clear data to help make comparability assessments.
  • 2017 Frost & Sullivan Predictions in Diagnostics
    2017 Frost & Sullivan Predictions in Diagnostics Transformational Health Team, Harry Glorikian, Board Advisor and Eunice Teo, Director, Business Development, QuantuMDx Recorded: Mar 23 2017 64 mins
    The global clinical diagnostics industry is undergoing a transformation propelled by laboratory consolidation and automation, an enormous move toward data-driven healthcare, large investments in unifying technologies, and renewed business models driven by products and value-added services. There is immense pressure on companies to radically improve new product innovation, manufacturing, and distribution of technologies such as point-of-care molecular diagnostics to capture new growth opportunities in the precision medicine market.
  • Introduction to Publishing for Early Career Researchers in Latin America
    Introduction to Publishing for Early Career Researchers in Latin America Dr Costas Agalou, Dr Serena Tan, Eduardo Martinez, Vicky Kinsman Recorded: Mar 22 2017 61 mins
    Learn more about the process of writing and submitting your research with practical tips on selecting the right journal, writing your article, understanding the peer review process and post-publication SEO and promotion. Register for your place today and discover all you need to help you successfully publish your next article.

    Discover all you need to know to start publishing with success!
    Do you struggle to find the right journal?
    Do you want advice on how to write and submit your paper?
    Do you want to understand the peer review process?
    Would you like tips on how to how to maximize the impact of your research?

    …then join our webinar and ask our expert editors, Dr Costas Agalou and Dr. Serena Tan, your questions.
  • Diagnostic and Therapeutic Patent and License Strategies
    Diagnostic and Therapeutic Patent and License Strategies Dr. Lisa Haile, Co-Chair, Global Life Sciences Sector at DLA Piper Recorded: Mar 22 2017 48 mins
    Dr Lisa Haile presents this webinar exploring issues and strategies for diagnostic and therapeutic patents and licenses.

    This webinar will address questions such as:
    Are diagnostic tests patentable?
    What are the effects of the Alice ruling and the Myriad Genetics case on patents?
    What strategies can be used to avoid the pitfalls associated with patenting around "laws of nature"?
    What are the latest rulings and precedents around diagnostics and genetic markers and how is the landscape evolving?

    This is essential viewing for anyone involved with intellectual property and innovation in the life sciences sector.
  • The medical physics revolution continues:  the next 60 years
    The medical physics revolution continues: the next 60 years Robert Jeraj, Professor, Medical Physics, University of Wisconsin Recorded: Mar 22 2017 48 mins
    In the fifth and final of our series of webinars showcasing presentations from the PMB 60th Anniversary Symposium, Robert Jeraj from the University of Wisconsin takes a look at what may lie ahead for medical physics in the next 60 years.
  • New Ways to Boost Sales Productivity in 2017 [Panel Discussion]
    New Ways to Boost Sales Productivity in 2017 [Panel Discussion] Gerhard Gschwandtner (Moderator); Anthony Iannarino, Teja Vora Recorded: Mar 21 2017 57 mins
    A new year, a new strategy, and new tools for winning sales! Join us for this webinar to get the inspiration and tips you need to set your intention to make 2017 the year of hustle, value creation, and digital transformation. Bestselling author and award-winning blogger, Anthony Iannarino, will share his top sales insights in this interactive webinar that welcomes audience participation and questions.

    Key takeaways for this webinar will include
    - The year of hustle. Learn how to create the right mindset and skillset to stay a step ahead of your competition.
    - The year of value creation. Discover how top performers focus on value creation - Anthony will share his secret sauce for winning more sales.
    - The year of digital transformation. Learn how to avoid time-wasting technology and social media traps and instead leverage the best tools to work 100 percent smarter, not harder.

    Moderator: Gerhard Gschwandtner, Founder & CEO, Selling Power
    Speakers: Anthony Iannarino, Bestselling Author and Sales Leader
    Teja Vora, Director of Marketing, DocuSign
  • Sanger Arrayed CRISPR Screening in partnership with Evotec
    Sanger Arrayed CRISPR Screening in partnership with Evotec Dr. Hauke Cornils-Res Scientist, Evotec & Shawn Shafer-Dir. Advance Genomics Life Science Business of Merck KGaA, Darmstadt, Recorded: Mar 16 2017 50 mins
    CRISPR Cas9 nucleases have revolutionized the field of gene editing and high-throughput lentiviral screens continue to hold ever-increasing promise for both basic research and development of future therapies to benefit human health. Even with such powerful technologies at hand, researchers new to the field may find the screening of multiple targets to be challenging and time-consuming. This webinar discusses the Evotec partnership with Life Science Business of Merck KGaA, Darmstadt, Germany and the screening services for drug discovery.
  • Part 2: Tumor heterogeneity and immuno-oncology
    Part 2: Tumor heterogeneity and immuno-oncology Tom Grogan, MD, Founder, Senior Vice President, Ventana Medical Systems Inc. Recorded: Mar 15 2017 2 mins
    View two new CDx Insights videos “Part 1: CDx, IHC and tumor heterogeneity” and “Part 2: Tumor heterogeneity and immuno-oncology” with Tom Grogan, MD, Founder and Senior Vice President of Scientific Affairs of Ventana Medical Systems, Inc. Dr. Grogan addresses the role of IHC in companion diagnostics, assessment of heterogeneity and the interplay between the immune system and cancer.
  • Part 1: CDx, IHC and tumor heterogeneity
    Part 1: CDx, IHC and tumor heterogeneity Tom Grogan, MD,Senior Vice President, Founder, Ventana Medical Systems Inc. Recorded: Mar 15 2017 4 mins
    View two new CDx Insights videos “Part 1: CDx, IHC and tumor heterogeneity” and “Part 2: Tumor heterogeneity and immuno-oncology” with Tom Grogan, MD, Founder and Senior Vice President of Scientific Affairs of Ventana Medical Systems, Inc. Dr. Grogan addresses the role of IHC in companion diagnostics, assessment of heterogeneity and the interplay between the immune system and cancer.
  • Approval and access: Overcoming the final hurdle of drug development
    Approval and access: Overcoming the final hurdle of drug development Professor Luca Pani, University of Miami, Angelika Joos,MSD (Europe) Inc. Ana Palma, Sobi, Belgium Recorded: Mar 10 2017 61 mins
    2017 is once again a year of significant change for pharma market access in Europe, with affordability on the agenda for almost every country in the region. There is a move toward greater collaboration in health technology assessment and more transparency between countries for pricing, therapeutic protocols and and details of negotiations with drug manufacturers. We also see member states working to understand the process of enabling cost-effective patient access to personalised and high-cost treatments, such as new oncology combination therapies, antibiotics and stem cell therapies, which offer the promise of efficacy in key disease areas.

    With market access being referred to as the “fourth hurdle” in drug development (beyond efficacy, safety and quality), it is vital that the requirements for both approval and access are addressed early in the process. Parallel scientific advice from HTA bodies and regulators is increasing to deliver tangible and successful strategies, but is the process smooth enough to overcome the challenges from both sides?

    pharmaphorum in partnership with DIA will be hosting an expert panel debating the best way forward for life sciences companies, payers and providers in this emerging European market access paradigm.

    Join our webinar to hear from experts in industry and healthcare discussing the challenges and solutions of access in the changing European market.
    Topics up for discussion include:
    •Integrating HTA and regulatory strategy – the best way forward
    •Regional variation and implication – how to efficiently and effectively navigate EU market access
    •Proving value – how to leverage real world evidence to meet increasing demands for observational data
    •Future proofing market access – how to improve upon evidence generation and use technology effectively and competitively
  • REACh Regulation Update
    REACh Regulation Update Dr Joachim Buenger-Associate Director of Corporate Regulatory Affairs & Dr Lisa Fitzpatrick, WEU Field Marketing Manager Recorded: Mar 10 2017 17 mins
    As you are aware, Triton will soon be included in the Authorization list (Annex XIV) of REACh. In order to continue to supply this material, we need some detailed information from you. In anticipation of your questions, we are hosting a webinar to answer as many of these queries as we can.
  • Introduction to Publishing for Early Career Researchers in India
    Introduction to Publishing for Early Career Researchers in India Katy Dillon, Anne Nijs, Vicky Kinsman Recorded: Mar 1 2017 48 mins
    Discover what successful researchers do to get published!
    Do you need advice on finding the right journal? Does peer review feel like a mystery? Do you want tips on how to maximize the impact of your research? Do you want to connect with our experienced editors in real-time? …well this is the webinar for you!
    In this practical webinar you'll hear expert publishing advice from Katy Dillon, Associate Journals Editor for the Journal of the Science of Food and Agriculture, Anne Nijs, Deputy Editor, European Journal of Organic Chemistry and Vicky Kinsman, Wiley Author Services. Register for your place today and learn all you need to know to start feeling confident about publishing your next research paper.
  • Simulating Electromagnetic Communication & Interference with COMSOL Multiphysics
    Simulating Electromagnetic Communication & Interference with COMSOL Multiphysics Dr Simone Zonetti, Applications Engineer, COMSOL Recorded: Feb 28 2017 60 mins
    The physics of electromagnetic coupling through space is fundamental to modern technology. It is exploited in some devices such as RFID tags and directional couplers to communicate information. In other devices, electromagnetic interference (EMI) is an unwanted effect that must be controlled: for example, the problem of crosstalk in electrical circuits and cables. In this webinar we will discuss the simulation of electromagnetic coupling in a variety of different applications, considering examples of capacitive, inductive and radiative couplings in frequencies from the kHz to GHz range. We will show how modelling can provide insight into design, either to improve the quality of a communication device, or to mitigate EMI through effective electromagnetic shielding. A live demo will illustrate how to simulate antenna crosstalk using COMSOL Multiphysics®. We will conclude this webinar with a Q&A session.
  • Surfaces for Organoid Culture
    Surfaces for Organoid Culture Nitin Kulkarni, Ph.D. Recorded: Feb 23 2017 50 mins
    3D culture is gaining pivotal importance for attaining in vivo-like conditions in a dish to study developmental cues as well as therapeutic possibilities. Organoid development promises to be one of the most important research tools in the near future. This presentation will cover:

    • Methodologies used in organoid culture
    • Matrices for growing organoids
    • Recovery of organoids for downstream applications

    Speaker Bio:

    Dr. Nitin Kulkarni is a member of the Scientific Support team at Corning Life Sciences. He has a Ph.D. in Biology and has worked on engineering transgenic mouse models for autoimmune diseases during his post-doctoral research at the Beth Israel Deaconess Medical Center in Boston, MA.
    In his current role, he supports researchers with applications related to cell culture including advanced surfaces and extracellular matrices, genomics, drug discovery and bioprocesses.
  • Subvisible Particle Identification & Characterisation by Multi-Technique Methods
    Subvisible Particle Identification & Characterisation by Multi-Technique Methods Dr Jonas Hoeg Thygesen & Colin Merrifield Recorded: Feb 23 2017 61 mins
    Observable foreign and particulate matter has for a long time been recognized as a critical quality attribute for production of injectable protein formulations. Recently, a focus shift towards these particles and even smaller particles (particulate matter or subvisible particles) has been seen from the pharmaceutical industry, academia and the different regulatory bodies. Two of the central documents in this context are:

    1. The FDA Guidance for Industry on Immunogenicity Assessment for Therapeutic Protein Products1 and

    2. United States Pharmacopia Chapter 2
  • New horizons for adaptive therapy and dose guidance
    New horizons for adaptive therapy and dose guidance Katia Parodi, Chair of Experimental Physics – Medical Physics, Ludwig-Maximilians-Universität München Germany Recorded: Feb 22 2017 52 mins
    In the fourth of our series of webinars showcasing presentations from the PMB 60th Anniversary Symposium, Katia Parodi examines the key ingredients of modern adaptive radiotherapy, including fast computational models and methods for in-vivo dose/range assessment. She also takes a look forward to the era of biological guidance.
  • How do you Decide Whom to Biopsy for Prostate Cancer?
    How do you Decide Whom to Biopsy for Prostate Cancer? Dr. E. David Crawford Recorded: Feb 17 2017 61 mins
    In our webinar, Identifying Men with Prostate Cancer—The Role of phi and Other Biomarkers, Dr. E. David Crawford will discuss key issues that challenge a physician's ability to make informed decisions regarding whom to biopsy for prostate cancer. After the webinar, you will be able to:

    • Understand the historical perspective and controversy regarding prostate-specific antigen (PSA) screening

    • Improve your interpretation of a PSA result

    • Use biomarkers, such as Prostate Health Index (phi), to reduce negative biopsies and have more confidence in the decision to biopsy

    • Understand how the phi score, combined with family and patient history, can determine patient management decisions

    Dr. Crawford is an internationally renowned urologist and distinguished endowed professor of surgery, urology and radiation oncology. He also serves as the head of the section of urologic oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles.
  • Implementing MRI and MR-SIM for Radiation Oncology:  What you need to know
    Implementing MRI and MR-SIM for Radiation Oncology: What you need to know Carri K Glide-Hurst, PhD, DABR Senior Staff Physicist, Henry Ford Health System Recorded: Feb 15 2017 61 mins
    Almost all clinics, small and large, use magnetic resonance images (MRI) in their treatment-planning workflows. Modern treatment planning requires images of high geometric fidelity with high spatial and contrast resolution to delineate disease extent and proximity to adjacent organs at risk. However, imaging protocols needed for accurate treatment planning differ significantly from those used in diagnostic radiology. As the integration of MRI into radiation oncology is expanding rapidly, a need exists to highlight the considerations for safe and effective implementation. This webinar will describe the major differences from diagnostic MRI, provide an overview of MRI safety and training models, introduce clinical-workflow considerations, and describe the development of a robust quality-assurance programme. Special considerations for motion management and treatment planning will be described.
  • Challenges and Successes in Externalization of the ADC Supply Chain
    Challenges and Successes in Externalization of the ADC Supply Chain Firelli Alonso, Ph.D. Recorded: Feb 14 2017 74 mins
    Sourcing for the manufacture and control of Antibody-Drug Conjugates (ADCs) used in clinical trials requires strategic planning, establishment of a specialized support network, and execution of several interdependent tasks. ADCs are complex molecules, a fusion of a biological, the monoclonal antibody (mAb), and of small molecules, the linker and the toxic payload. Facilities of acceptable standards for the handling of high potency materials need to be engaged, and there is a limited supply currently. This is further complicated by the fact that there is not one contract facility that has fully integrated services, a “one-stop shop” capable of mAb production, linker and/or payload synthesis, conjugation of mAb to linker-payload to make the Drug Substance, and finally, formulation of the ADC to make the Drug Product. Strategizing the best outsourcing practices for producing and testing ADCs, and establishing guiding principles for externalization to ensure the selection of the right CMOs for ADC outsourcing and technology transfer, will be further discussed.
  • Continuous Bioprocessing: PAT for Process Monitoring & Control to enable RPR
    Continuous Bioprocessing: PAT for Process Monitoring & Control to enable RPR Jeff Doyle and Dr Paul Jeffers Recorded: Feb 7 2017 57 mins
    Continuous bioprocessing offers potential to enhance productivity and product quality uniformity while simultaneously decreasing facility footprint and associated operational overhead. Advances in technology and increasing commercial pressures are leading to an increased interest in continuous processing across the biopharmaceutical sector. A number of companies are exploring and advancing continuous bioprocessing and this presents a range of opportunity and challenges, including the use of Process Analytical Technology (PAT) for process characterization, process control, and process robustness, in support of a Rapid Product Release (RPR) strategy.
  • Rescheduled: Multicellular Tumor Spheroids in HTS: New Assays
    Rescheduled: Multicellular Tumor Spheroids in HTS: New Assays Wojciech Senkowski Recorded: Feb 1 2017 50 mins
    Three-dimensional cell cultures, and multicellular tumor spheroids in (MCTS) in particular, have recently become a widely used tool for preclinical anticancer drug testing in high-throughput screening (HTS) setup. However, even though MCTS have been applied for HTS, their use has been limited to simple assays, such as assessing cell viability or inhibition of growth.

    This webinar will cover new approaches to MCTS-based HTS. It will present a new, robust viability assay, well-suited for HTS and based on green fluorescent protein (GFP) used as a surrogate marker of spheroid viability. It will also review a first-ever approach to obtain information-rich transcriptomic data from drug-treated MCTS on a large scale. In addition, the presenter will demonstrate how this novel platform resulted in the identification of previously unrecognized, context-dependent drug responses of cancer cells and in findings with potential clinical relevance.

    In summary, this webinar will demonstrate new ways of how MCTS-based HTS can be used to provide unique insights into context-dependent biology and cellular drug responses.

    About the Presenter:

    Wojciech Senkowski will soon complete his Ph.D. in Medical Sciences at Uppsala University, Sweden. In his work, he looks for applications of various tumor spheroid models in high throughput drug screening. For his work, Wojciech has received the AACR Scholar-in-Training Award. He was also a presenter and expert panelist at the Genetic Engineering & Biotechnology News webinar on 3D cell cultures, sponsored by Corning in February of 2016.
  • Disruptive forces in technology and the implications for healthcare
    Disruptive forces in technology and the implications for healthcare Fonny Schenck (CEO Across Health) Mar 30 2017 3:00 pm UTC 45 mins
    Live Webinar on March 30 at 5pm CET
    Life Sciences is an industry full of established, large companies with significant barriers to entry and often long legacies of success. But the weather is changing – and the structures and strategies which have kept these enterprises safe may soon become liabilities. What is only just becoming clear, though, is how fast this is happening. Along all key areas of the value chain, new & nimble competitors are entering the scene - and they are playing a totally different game.

    Find out more about these disruptive trends, get the highlights of our second ‘Healthcare Disruption Tour’, which went to the heart of the action in Jan 2017, and learn why pharma should take note…and how it can best prepare & organize for this tsunami.

    Topics:
    • Key trends in healthcare disruption
    • Impressions from the second healthcare disruption tour
    • Embedding disruption in pharma organisations
  • Enabling CAR-T Screening in 3D Tumor Spheroids
    Enabling CAR-T Screening in 3D Tumor Spheroids Van Dang, D.V.M., Ph.D., Abhi Saharia, Ph. D., and Audrey Bergeron, Applications Scientist Mar 30 2017 4:00 pm UTC 60 mins
    Webinar Date & Time: Mar 30 2017 12:00 p.m. EST

    Chimeric antigen receptor (CAR)-T cells, which are engineered to recognize target cell surface antigens expressed on tumor cells, have shown promise to affect complete remission in patients with B-cell malignancies. However, applying this approach to target solid tumors has resulted in adverse effects in clinical studies. Methods for testing different models of CAR-T cells in vitro can provide further insight into viable antigen targets. Historically, two-dimensional (2D) cell culture models have been used in drug discovery. However, more elaborate, three-dimensional (3D) cell culture models better mimic the in vivo tumor microenvironment and help bridge the gap between in vitro studies and clinical outcomes.

    In this special joint webinar, panelists from ProMab Biotechnologies, DiscoverX, and Corning Life Sciences will present data on a high-throughput, easy-to-use, highly reproducible method for screening CAR-T cells in a 3D cell culture model by combining various technologies.


    Speakers:
    Van Dang, D.V.M., Ph.D.
    Scientist and coordinator for CAR-T research
    ProMab Biotechnologies, Inc.

    Abhi Saharia, Ph. D.
    Director, Cell-based Assays and Biologics
    DiscoverX

    Audrey Bergeron
    Applications Scientist
    Corning Life Sciences
  • Single Use Systems in Biologics Manufacturing & their Impact on Operational Tech
    Single Use Systems in Biologics Manufacturing & their Impact on Operational Tech Gloria Gadea-Lopez, John Maguire & Ken Clapp Apr 4 2017 1:00 pm UTC 75 mins
    The increased interest and adoption of single use systems (SUS) or disposables require that organizations rethink their operational business processes and the design and configuration of manufacturing execution systems (MES). Drawing from their previous experience implementing MES and SUS for biologics manufacturing, the authors discuss the key areas of impact of SUS on operational technology, outline new user requirements, and propose practical solutions for successful MES implementation.
  • When small becomes big: orphan medicines, advances, access and affordability
    When small becomes big: orphan medicines, advances, access and affordability Alastair Kent OBE, Malcolm Qualie, Sheela Upadhyaya, Sarah Rickwood, Moderated by Paul Tunnah Apr 10 2017 3:00 pm UTC 75 mins
    Over the past few years there has been a shift in the European pharmaceutical market landscape, with a rise in specialty medicines for diseases with narrow patient population. Indeed, QuintilesIMS forecasts that, between 2013 and 2018, 94% of list price value growth will be in specialty medicines – with orphan drugs at the forefront of this trend.
    On 10 April 2017, QuintilesIMS, in partnership with pharmaphorum presents a unique digital debate, bringing together a panel of senior industry experts, including participants from NICE, NHS England and Genetic Alliance UK to explore the pillars of commercial success for orphan drugs in Europe and review the wider implications of Brexit for the rare disease community.
  • 3D Bioprinting: From research lab to bedside
    3D Bioprinting: From research lab to bedside Dr. Scott Collins, CTO and VP of Research and Development at TeVido Apr 12 2017 3:30 pm UTC 60 mins
    TeVido BioDevices uses the innovative process of 3D bioprinting living human cells for use as implants or grafts for use in reconstructive surgery and wound care, for example in post-surgery care for cancer patients.

    TeVido uses a simple yet sophisticated approach to produce living tissue products - inkjet printers modified to print cells instead of ink.
    In this live webinar, Dr. Scott Collins, CTO and VP of Research and Development at TeVido, will explain TeVido’s innovation journey, from concept, through research and prototying, to funding, patenting, and testing the company’s highly innovative offering in the field of biotechnology.
  • Assessing early market opportunity
    Assessing early market opportunity Dominic Tyer Apr 19 2017 2:00 pm UTC 60 mins
    To successfully develop and launch an asset it’s crucial to identify and define the commercial value early in the process.

    On the 19th April Cello Health, in association with PMGroup, will host a free webinar which will discuss the background and context of early asset development and how to achieve a successful market assessment strategy.

    It will look at how marketers can understand the competitive market landscape as early as possible.
  • 3 Ways to Retool Your Business with Technology in 2017
    3 Ways to Retool Your Business with Technology in 2017 Andrea Bradbury, Co-Founder and Chief Quality Officer, Suvoda Software; Jeinnfer Royer, Direct Product Marketing, DocuSign Apr 25 2017 8:00 pm UTC 60 mins
    Nearly 50% of business leaders fear they will become obsolete over the next several years, and nearly 80% feel threatened by digital startups. Why? New technologies and digital strategies are challenging existing business models and forcing companies of all sizes to reimagine patient care, product innovation and distribution models to remain competitive.

    View this on-demand webinar hosted by PharmaVOICE to learn from Andrea Bradbury, Co-Founder and Chief Quality Officer, Suvoda Software, a leader operating at the intersection of life sciences and technology as she shares how she built her business on a digital platform to accelerate her organization’s global expansion while meeting the needs of mobile, digital customers and employees.

    Topics covered include:

    - Streamlining clinical research, sales and HR processes with digital tools
    - Elevating the digital agenda at your organization
    - Scaling technologies globally
    - Applying nimble design models for life science operations
    - Implementing top life sciences trends in 2017
  • Simulating MEMS and Smart Materials with COMSOL Multiphysics®
    Simulating MEMS and Smart Materials with COMSOL Multiphysics® Dr Robbie Balcombe, Technical Director, COMSOL Apr 27 2017 1:00 pm UTC 60 mins
    If you are interested in modelling smart materials and MEMS using COMSOL Multiphysics®, then tune into this webinar.

    Smart materials are materials whose properties or shape respond dynamically to stimuli in their environment. For example, piezoelectric materials experience strain under an applied electric field, while magnetostrictive materials deform in the presence of a magnetic field.

    In this live webinar, you will learn how to model MEMS sensors and actuators based on smart materials for a wide range of applications, including vibration and active shape control as well as structural health monitoring and energy harvesting. We will also demonstrate the applicability of the COMSOL Multiphysics® simulation environment for coupling mechanical, electrical and thermal models of smart materials.

    At the end of this webinar, you can ask questions during the Q&A session.
  • The benefits of gigahertz mode spacing for frequency comb applications
    The benefits of gigahertz mode spacing for frequency comb applications Dr Albrecht Bartels, managing director of Laser Quantum May 3 2017 2:00 pm UTC 60 mins
    After the first demonstration of an optical frequency comb based on a mode-locked laser in 1999, Ti:sapphire lasers with repetition rates around 1 GHz were the sources of choice for scientists around the world. Their key feature was a mode spacing 10 times higher than that of comparable 100 MHz sources (simplifying mode identification) and the ability to generate a fully coherent super-continuum with 100 times more power per mode either directly from the cavity or using an external microstructured fibre (enhancing signal-to-noise ratio). The world’s first optical atomic clock was built in 2001 using a 1 GHz Ti:sapphire laser and subsequently it has been shown that these lasers indeed support an accuracy at the 10–20 level with a 1 s stability at the 10–17 level and optical linewidths at the millihertz level, i.e. ideal candidate clockworks for a new generation of optical atomic clocks. The Ti:sapphire technology has even been taken out to as far as 10 GHz, a regime where individual modes with powers in excess of 1 mW can be separated with a grating spectrometer and used individually for direct spectroscopy, spectrograph calibration or optical arbitrary waveform generation.

    To overcome some of the disadvantages of early Ti:sapphire lasers (requirement for frequent alignment, cleaning and use of AO modulators for control purposes) and to make the full advantages of GHz frequency comb technology accessible to the science community, Laser Quantum has developed the hermetically sealed and permanently aligned taccor 1 GHz Ti:sapphire laser featuring an integrated pump laser with direct pump power control. This intervention free laser forms the basis for the new taccor comb system featuring an f-2f interferometer and full comb-stabilization electronics.

    This webinar reviews the benefits of gigahertz Ti:sapphire frequency combs and focuses on the recent progress using Laser Quantum‘s hermetically sealed line of taccor lasers.
  • Implementing Single-Use PAT at seed stage to simplify cell culture operations
    Implementing Single-Use PAT at seed stage to simplify cell culture operations Dr Jose R. Vallejos May 24 2017 2:00 pm UTC 75 mins
    Single-Use Process Analytical Technologies (PAT) tools have a great potential to not only increase process understanding at the seed stage but also simplify cell culture operations. By utilizing PAT, the risk from bioburden or contamination can be significantly reduced and the overall operating efficiency increased. In fact, PAT also provides a data-driven platform to integrate Process Development and Manufacturing Operations that can mitigate risks associated with technology/process transfer.
  • Multichannel Rep
    Multichannel Rep Annelien Van Boxlaer (VP Innovation Strategy, Across Health) & Patrick Vidal (MD, Across Health France) May 30 2017 3:00 pm UTC 60 mins
    The world of the field force is changing. Increased digitalisation, powerful new tools and a growing expectation that they ‘conduct’ multiple channels means new skills, ways of working, and even thinking, are needed.

    This shift will radically change the structure of the traditional Pharma organization. Differences between HQ and local offices will become less pronounced as the field force gains the ability to deploy highly tailored, right-on-time content, in the best possible format for individual physicians.

    Find out more about how the time of the Multichannel Rep is now, how upskilling and reskilling are the buzzwords for new engagement models, and how not to have your field force being left behind in the digital race!

    Topics include:
    •Getting the right digital tools into the hands of reps
    •How to evaluate what the best channels for your situation are
    •Finding out what good looks like
    •How to engage your field force, manage the change, and sustain their motivation
  • Challenges in the Development of Continuous Processes for Vaccines
    Challenges in the Development of Continuous Processes for Vaccines Danny Vellom Jun 7 2017 2:00 pm UTC 75 mins
    The development and application of continuous manufacturing processes for vaccines presents both great opportunity as well as significant challenges, both technical and cultural, for the global industry. The key drivers are manufacturing capacity and flexibility, speed to market, and improved quality through the application of Quality-by-Design and Process Analytical Technology (QbD/PAT). Given the diversity of immunogens (toxoids, conjugate and subunit vaccines, live-attenuated and inactivated viruses, VLPs, etc.), and the variety of unique processes currently utilized to produce either single- or multi-component vaccines, it is unlikely that the transition to continuous processing will happen overnight. Additionally, cultural challenges are faced whenever a new mode of operation appears to some as “too different”, especially in a traditionally conservative sector like the developed-world vaccine industry. That said, market forces, global climate change, and Nature’s propensity to fill unoccupied niches with emerging infectious diseases will undoubtedly induce a first round of pioneers to explore this exciting new design space, ultimately leading to a more nimble industry and more and better opportunities for protection for the global population.
  • Modernizing Biopharmaceutical Manufacturing: From Batch to Continuous Production
    Modernizing Biopharmaceutical Manufacturing: From Batch to Continuous Production Robert Dream Jul 19 2017 2:00 pm UTC 75 mins
    The importance and value of continuous bioprocessing, both upstream and downstream has economic and sustainability advantages and due to the modular nature of continuous bioprocesses means that industry is able to adapt more rapidly to changing market demands. Continuous biopharmaceutical manufacturing in the context of other industries that have already successfully adopted continuous processing. Factor other than scientific ones, are the barriers to change from batch to continuous production. an excellent example of the manufacturing strategies of the steel industry in the 20th century, when this industrial sector incrementally switched from batch to continuous operations. biopharmaceutical industry has reached a stage that requires a change in the production paradigm. For a certain class of biopharmaceutical products upstream continuous manufacturing has always been applied: for example, unstable proteins that rapidly degrade in the culture broth. In order to obtain a high quality product, the residence time in the reactor must be minimized. This can only be achieved with continuous cultivation and preferably with perfusion reactors. a brief overview on the types of cell retention devices currently used in biopharmaceutical industry.
    Furthermore, this is a universal production platform that can be extended to other classes of products, such as antibodies, which are relatively stable molecules. continuous manufacturing is as productive and with a much smaller footprint of the manufacturing plant, avoiding multiple non-value added unit operations. In essence, the investment for a continuous plant is much smaller compared to a batch-operated one.
  • New Paradigm of Building Quality during Manufacture - Challenges with Biologics
    New Paradigm of Building Quality during Manufacture - Challenges with Biologics Dr Rajesh K. Gupta Aug 23 2017 2:00 pm UTC 75 mins
    Historically, quality of biological products has been ensured through testing representative samples. Shift in quality paradigm started with implementation of Good Manufacturing Practice (GMP) regulations with current focus on building quality during manufacture. Inherent variability and complexity of biological products pose challenges in implementing Quality by design (QbD) concept. This presentation discusses ways to build quality during manufacture of biological products.
  • Advances in Mass Spectrometry for the Analysis and Bioanalysis of Antibody-Drug
    Advances in Mass Spectrometry for the Analysis and Bioanalysis of Antibody-Drug Arnaud Delobel, PhD Sep 12 2017 2:00 pm UTC 75 mins
    ADCs are complex compounds resulting from the coupling of cytotoxic small molecules to a monoclonal antibody. Their characterization as well as their bioanalysis (quantification in biological fluids) remains challenging. Mass spectrometry at different levels (intact, middle, peptide) can be a valuable tool, and can now be used in a regulated environment thanks to advances in both hardware and software.